DIRS.INFO The most relevant business & tech news

☆ Obesity drugs will be the largest pharamaceutical class ever, says Emily Field
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity drugs will be the largest pharamaceutical class ever, says Emily FieldEmily Field, Director and Lead Analyst of European Pharmaceuticals at Barclays, discusses weight-loss and GLP-1 drugs.

Persons: Emily, Emily Field Organizations: European Pharmaceuticals, Barclays

☆ Obesity 'bolt-ons' likely to spur pharma M&A in 2024: Analyst
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity 'bolt-ons' likely to spur pharma M&A in 2024: AnalystEmily Field, director and head of European pharmaceuticals equity research at Barclays, says the industry is likely to see an uptick in mergers and acquisitions in 2024, especially with smaller deals in the obesity drugs space.

Persons: Emily Field Organizations: pharma, Barclays

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

☆ Eli Lilly and Novo Nordisk will remain winners in the weight-loss category: Barclays' Emily Field
▼ + stars: | 2023-11-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain winners in the weight-loss category: Barclays' Emily FieldEmily Field, Barclays, joins 'Squawk Box' to discuss the latest news in the weight-loss drug market, the news to watch out for next year, and how investors should play the weight-loss drug market.

Persons: Eli Lilly, Emily, Emily Field Organizations: Novo Nordisk, Barclays

☆ Wegovy slashes risk of serious heart events: What this means for patients and insurers
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWegovy slashes risk of serious heart events: What this means for patients and insurersEmily Field, head of European Pharmaceutical Research at Barclays, joins 'Squawk Box' to discuss a new study that suggests that the weight-loss drug Wegovy reduces the risks of heart attacks, what these results mean for patients and insurers, and more.

Persons: Emily Field Organizations: European Pharmaceutical Research, Barclays

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. "Supply of Wegovy is the most important thing for specialist healthcare investors covering Novo right now," said Barclays analyst Emily Field. Some analysts said a firm date would ease concerns that Novo's supply constraints could allow rival Eli Lilly (LLY.N) to get ahead, when it launches its Mounjaro weight-loss drug. Eli Lilly, the world's most valuable drug company ahead of Novo, has said it expects U.S. approval for the drug, currently licensed for diabetes, to be used for weight loss by the end of the year. Novo is spending billions to increase Wegovy output and hiring more contract manufacturers to fill the pens.

Persons: Victoria Klesty, Wegovy, Novo, Emily Field, Eli Lilly, Markus Manns, Manns, Catalent, Jefferies, Jacob Gronholt, Pedersen, Maggie Fick, Josephine Mason, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wegovy, Barclays, U.S . Food, Drug Administration, Union Investment, Thomson Locations: Oslo, Norway, Victoria, COPENHAGEN, United States, Danish, Germany, Novo, U.S, Brussels, London

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

☆ Novo Nordisk stops Ozempic kidney trial after early signs of success
▼ + stars: | 2023-10-10 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Novo said the trial would be halted almost a year early based on a recommendation from the independent data monitoring board overseeing the study. Independent monitors can recommend stopping a trial early if there is clear evidence that a drug was going to succeed or fail based on interim analyses. Semaglutide is also the active ingredient in Novo Nordisk's powerful weight-loss drug Wegovy. Novo's success has also created an economic boom for Denmark, according to Danish economists, analysts, and executives at the Novo Nordisk Foundation.

Persons: Tom Little, Novo, Danish drugmaker, Wegovy, Emily Field, Patrick Wingrove, Sriparna Roy, Bill Berkrot Organizations: REUTERS, Novo Nordisk, Barclays, Novo Nordisk Foundation, Thomson Locations: Hillerod, Denmark, Danish, New York, Bengaluru

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ Barclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug race
▼ + stars: | 2023-08-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBarclays: Novo Nordisk and Eli Lilly have first-move advantage in the obesity drug raceEmily Field, Head of European Pharmaceutical Research at Barclays, discusses Novo Nordisk, Eli Lilly, and competition in the weight-loss/obesity drug space.

Persons: Eli Lilly, Emily Field Organizations: Barclays, Novo Nordisk, European Pharmaceutical Research

☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
▼ + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +3 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.

Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S

☆ Strong U.S. demand eases pressure on Novo to show weight-loss drug's health benefits
▼ + stars: | 2023-07-14 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

Investors had been banking on the study results being the next big driver of the company's shares. That's due to high demand and after Novo raised its profit outlook in April, said Berenberg analyst Kerry Holford. If the risk reduction was between 10 and 14%, shares would decrease by less than 5%. A year ago, investors said a risk reduction of 10 to 14% in the trial would put significant downward pressure on the stock, Holford said. Barclays analyst Emily Field said a risk reduction as low as 11% could boost the stock.

Persons: Novo, Kerry Holford, Holford, Emily Field, Maggie Fick, Josephine Mason, Alexandra Hudson Organizations: Soaring U.S, Novo Nordisk's, Nestle, UBS, Reuters, Barclays, May, BMO Global Asset Management, Alexandra Hudson Our, Thomson Locations: Danish, United States

GSK on Friday said the settlement reflected its desire to avoid distraction related to protracted litigation in this case. It did not admit any liability and said it would vigorously defend itself in any other Zantac cases. The trial was due to start on July 24, the first test of how Zantac cancer claims would fare before a jury. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, said the Goetz settlement could create a precedent to settle other cases. "It also removes the distraction of any protracted litigation as the company must focus on its future pipeline which is where value will be created for shareholders," she said.

Persons: drugmaker, James Goetz, Emily Field, Lucy Coutts, JM Finn, Goetz, Dado Ruvic, Boehringer Ingelheim, Zantac, Natalie Grover, Eva Mathews, Dhanya Ann Thoppil, Barbara Lewis Organizations: GSK, Barclays, GlaxoSmithKline, REUTERS, Pfizer, Sanofi, Companies, Bank of America, FDA, Thomson Locations: U.S, British, California, Delaware, London, Bengaluru

☆ This weight-loss drug maker's stock is up 20% this year — and Barclays sees it going higher
▼ + stars: | 2023-04-28 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Wegovy catapulted into the spotlight thanks to its success in weight loss and the endorsement by celebrities and social media influencers, including Tesla CEO Elon Musk. However, some investors are concerned that Novo's stock has already factored in this growth potential, as its shares have risen by 137% since the U.S. Food and Drug Administration approved the drug in June 2021. Novo's shares are also traded in New York Stock, London , and Frankfurt. NVO 5Y mountain According to Barclays' Field, the market for obesity treatment drugs could be worth as much as $200 billion within the next decade. "So does the weight loss that comes with taking Wegovy prevent you from having a heart attack or a stroke among those that have a higher risk?

The trial will be the first test of how Zantac cancer claims will fare before a jury. GSK said in a statement it disagreed with the ruling and would defend the case at trial. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer (PFE.N), Boehringer Ingelheim and finally Sanofi (SASY.PA). While NDMA is found in low levels in food and water, it is known to cause cancer in larger amounts. Analysts said it was not surprising that Grillo ruled differently from the federal court because California's courts are known to be friendlier to plaintiffs.

The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure. Sales of its best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — came in just below estimates from Cowen analysts. Sales started to pick up in the second half of 2022 and in the fourth quarter grew by 3% at constant currency rates. Of key interest to investors is the experimental cancer drug, datopotamab deruxtecan, being evaluated in a keenly anticipated late-stage trial involving lung cancer patients. Partner Daiichi Sankyo (4568.T) this month said results of that study have been delayed to the second quarter from the first quarter of 2023.

On Wednesday, the company reported adjusted fourth quarter profit of 25.8 pence per share on sales of about 7.4 billion pounds ($9.11 billion). At 0900 GMT, GSK shares were up 0.4% outperforming the FTSE 100 which was up 0.3%. U.S. litigation over the heartburn drug Zantac has also spooked investors, hurting GSK's shares in the second half of 2022. "Nevertheless, against the backdrop of recent performance, and without any contribution from Covid-19, GSK’s 2023 guidance demonstrates some improved momentum," he said. GSK's shares have lagged most of its rivals in recent years.

LONDON, Feb 1 (Reuters) - GSK (GSK.L) chief executive Emma Walmsley on Wednesday made replenishing the drugmaker's pipeline of vaccines and therapies her number-one priority. But analysts say there is not enough in the medicine cabinet to keep the momentum going even beyond the next few years. Meanwhile, analysts say the market for Shingrix will eventually become saturated, further limiting the company's growth prospects. GSK shares lagR&D SPENDGSK's spending on R&D has long lagged behind its peers, something activist investor Elliott highlighted in a 2021 letter pressuring the company to make sweeping changes. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, there is hope the company will eventually deliver a streamlined and specialist portfolio of blockbuster drugs.

The two companies are in arbitration to decide what Sanofi's obligations might be, given Sanofi acquired the marketing rights to Zantac from Boehringer in 2017. A decision was initially expected by the end of 2022. Now, Sanofi sees it some time this year, and at the end of the first quarter at the earliest. Originally marketed by a forerunner of GSK (GSK.L), the medicine has been sold at different times by companies including Pfizer (PFE.N), Boehringer and Sanofi as well as several generic drugmakers. On Wednesday, Sanofi also said it expected fourth-quarter results next month to benefit from a stronger dollar and flu vaccine sales.

One of the biggest makers of generic drugs, Israeli-based Teva said it aims eventually to secure a 10% global market share of biosimilars. A division of Novartis (NOVN.S), Sandoz is currently the second biggest player after Pfizer Inc (PFE.N) in the biosimilar market by gross sales globally, per IQVIA data, cited by Sandoz. Sandoz launched eight biosimilar drugs between 2017 and 2021, including a version of Bristol-Myers’ multiple myeloma drug Revlimid. The analysis projected the value of the global biosimilar market could more than triple to an estimated $74 billion by 2030. Sandoz and Teva are both working on biosimilars for Humira.

The news marks a second setback for GSK's oncology portfolio this week, after the company on Monday revealed its blood cancer drug Blenrep failed to outperform an older therapy in a key study, calling into question Blenrep's existing U.S. approval. Zejula belongs to a family of drugs called PARP inhibitors - which include AstraZeneca (AZN.L) and Merck's (MRK.N) Lynparza and Clovis Oncology's (CLVS.O) Rubraca. In September, GSK withdrew the use of Zejula in certain ovarian cancer patients who had previously undergone three or more chemotherapy regimens. For GSK, Zejula's use in the first-line setting - as a therapy designed to keep cancer at bay in ovarian cancer patients who have partially or fully benefited from platinum-based chemotherapy, remains a priority. Zejula - which GSK acquired through its $5.1 billion acquisition of U.S. cancer specialist Tesaro in 2018 - generated a total of 120 million pounds ($141.4 million) last quarter.

Nu este clar însă cât de mulți producători de vaccinuri se vor îmbogăți și mai mult. Datorită nevoii urgente de vaccin, guvernele și donatorii au investit miliarde în proiecte pentru a le crea și testa. Abia atunci când guvernele și agențiile au intervenit cu promisiuni de finanțare au început să lucreze la asta. Guvernele și organizațiile multilaterale s-au angajat deja să cumpere miliarde de doze la prețuri stabilite. O lansare cu succes a vaccinurilor ar putea ajuta la deschiderea ușilor pentru vânzarea terapiilor Covid sau a altor produse.

Persons: Gates, Jack Ma, Dolly, Johnson, Emily Field, Rasmus Bech Hansen, Ellen, Field Organizations: americană, Universitatea din, Law, BBC, Reuters Locations: BioNTech, Germania, SUA, Universitatea din Oxford, India, Africa de Sud, Getty

Search resuls for: "Emily Field"

22 mentions found